Motilal Oswal Nifty MidSmall Healthcare Index Fund
- NAV as on 6 Nov 2026
- ₹12.71+0.36%1 day
- Return since launch
- 12.1%
- 52-week range
- ₹9.84 — ₹12.73
- AUM
- ₹52.54 Cr
Motilal Oswal Nifty MidSmall Healthcare Index Fund is a Sectoral-Pharma equity fund from Motilal Oswal Mutual Fund with ₹52.54 Cr under management, launched in 2024. The expense ratio is 1.22% and the SEBI riskometer reading is Very High.
Performance
Motilal Oswal Nifty MidSmall Healthcare Index Fund NAV and returns
Growth of the fund against its category average over the period you pick.
Over 1Y this fund returned +19.7% against +16.7% for its category.
Performance
Returns
How the fund has done against its category and its benchmark.
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1Y | 26.8% | +8.7 pts | 18.1% | 23.5% |
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1M | 4.0% | +0.2 pts | 3.9% | 5.6% |
| 3M | 0.7% | −0.5 pts | 1.2% | 0.9% |
| 6M | 11.3% | −0.8 pts | 12.1% | 10.6% |
| 1Y | 19.7% | +1.6 pts | 18.1% | 16.3% |
Since launch (29 Oct 2024): 12.1%
Calendar-year returns
Category averageShow as a table
| Period | Fund | vs category | Category |
|---|---|---|---|
| 2025 | -1.5% | +0.6 pts | -2.0% |
Returns over one year are annualised. Shorter periods are absolute.
Costs & terms
Costs and terms
What the fund charges each year, and the rules around putting money in and taking it out.
Costs
1.20%
Expense ratio as on 6 Nov 2026
Charged yearly and already deducted from the NAV.
- Base expense
- 0.90%
- Brokerage
- 0.01%
- Transaction charges
- 0.00%
- Statutory levies
- 0.29%
- Exit load
- Exit load of 1%, if redeemed within 15 days.
- Lock-in
- None
Terms
- Min SIP
- ₹3,000
- Min lumpsum
- ₹5,000
- Plan
- GROWTH
- Fund type
- OPEN-ENDED
- Benchmark
- Nifty MidSmall Healthcare TRI
- Short-term capital gains
- Returns taxed at 20% if you redeem before 1 year
- Long-term capital gains
- After 1 year, returns above ₹1.25 lakh in a financial year are taxed at 12.5%
Risk
Risk
What the riskometer means for this fund, and how its ratios sit against the category.
Your principal is treated as being at very high risk — typically small cap, sectoral and thematic equity schemes.
Portfolio
Motilal Oswal Nifty MidSmall Healthcare Index Fund portfolio
Portfolio as of 30 Sep 2026
Asset allocation
- Equity100.1%
Market cap split
- Mid67.8%
- Small32.2%
- P/E
- 42.20
- P/B
- 5.27
Top holdings
| Holding | Sector | Weight | Value | 3M chg | 6M chg | 1Y chg |
|---|---|---|---|---|---|---|
| Laurus Labs Ltd. | Healthcare | 11.83% | ₹6.22 Cr | +9.31% | +7.34% | +6.20% |
| Lupin Ltd. | Healthcare | 7.57% | ₹3.97 Cr | +9.26% | +10.67% | +8.77% |
| Aurobindo Pharma Ltd. | Healthcare | 7.09% | ₹3.72 Cr | +6.89% | +6.93% | +5.75% |
| Fortis Healthcare Ltd. | Healthcare | 6.15% | ₹3.23 Cr | +7.86% | +7.87% | +9.59% |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 5.39% | ₹2.83 Cr | +5.23% | +6.10% | +5.58% |
| Alkem Laboratories Ltd. | Healthcare | 4.78% | ₹2.51 Cr | +5.14% | +5.89% | +5.80% |
| Mankind Pharma Ltd. | Healthcare | 4.35% | ₹2.29 Cr | +4.54% | +4.31% | +5.22% |
| Ipca Laboratories Ltd. | Healthcare | 4.11% | ₹2.16 Cr | +3.72% | +4.23% | +3.53% |
| Biocon Ltd. | Healthcare | 3.96% | ₹2.08 Cr | +4.70% | +4.90% | +3.89% |
| Gland Pharma Ltd. | Healthcare | 3.54% | ₹1.86 Cr | +3.13% | +2.57% | +3.01% |
| Sai Life Sciences Ltd. | Healthcare | 3.23% | ₹1.70 Cr | +2.68% | +2.54% | — |
| Krishna Institute of Medical Sciences Ltd | Healthcare | 3.06% | ₹1.61 Cr | +3.33% | +2.92% | +3.27% |
| Aster DM Quality Care Ltd. | Healthcare | 2.86% | ₹1.50 Cr | +3.13% | +3.22% | +2.69% |
| Neuland Laboratories Ltd. | Healthcare | 2.82% | ₹1.48 Cr | +2.53% | +1.97% | +2.37% |
| Wockhardt Ltd. | Healthcare | 2.68% | ₹1.41 Cr | +2.53% | +1.85% | +2.38% |
| Acutaas Chemicals Ltd. | Healthcare | 2.61% | ₹1.37 Cr | — | — | — |
| Ajanta Pharma Ltd. | Healthcare | 2.53% | ₹1.33 Cr | +2.27% | +2.25% | +1.92% |
| Dr. Lal Pathlabs Ltd. | Healthcare | 2.38% | ₹1.25 Cr | +2.02% | +1.94% | +2.26% |
| Abbott India Ltd. | Healthcare | 2.17% | ₹1.14 Cr | +2.09% | +2.57% | +2.90% |
| Piramal Pharma Ltd. | Healthcare | 1.97% | ₹1.03 Cr | +1.65% | +1.61% | +2.24% |
| Granules India Ltd. | Healthcare | 1.92% | ₹1.01 Cr | +1.86% | +1.71% | +1.42% |
| Narayana Hrudayalaya Ltd. | Healthcare | 1.90% | ₹1.00 Cr | +2.15% | +2.11% | +2.24% |
| Global Health Ltd. | Healthcare | 1.86% | ₹0.98 Cr | +1.77% | +1.55% | +2.10% |
| Onesource Specialty Pharma Ltd. | Healthcare | 1.84% | ₹0.97 Cr | +2.04% | +1.55% | +1.93% |
| Glaxosmithkline Pharmaceuticals Ltd. | Healthcare | 1.76% | ₹0.92 Cr | +1.60% | +1.80% | +2.09% |
| Anthem Biosciences Ltd. | Healthcare | 1.42% | ₹0.75 Cr | — | — | — |
| Natco Pharma Ltd. | Healthcare | 1.14% | ₹0.60 Cr | +1.32% | +1.66% | +1.35% |
| Cohance Lifesciences Ltd. | Healthcare | 1.11% | ₹0.58 Cr | +1.17% | +0.93% | +2.13% |
| Syngene International Ltd. | Healthcare | 1.06% | ₹0.56 Cr | +1.32% | +1.41% | +2.24% |
| Poly Medicure Ltd. | Healthcare | 0.98% | ₹0.52 Cr | +1.02% | +0.86% | +1.41% |
| Others | Others | -0.07% | ₹-0.03 Cr | +2.05% | +0.79% | +0.68% |
Sectors
Instruments
Recent changes
| Holding | From | To | Weight |
|---|---|---|---|
| Anthem Biosciences Ltd. | 0.00% | 1.42% | +1.42% |
| Pfizer Ltd. | 1.07% | 0.00% | -1.07% |
| Fortis Healthcare Ltd. | 7.12% | 6.15% | -0.97% |
| Laurus Labs Ltd. | 11.23% | 11.83% | +0.60% |
| Others | -0.31% | -0.83% | -0.52% |
| Biocon Ltd. | 4.43% | 3.96% | -0.47% |
| Lupin Ltd. | 8.01% | 7.57% | -0.44% |
| Wockhardt Ltd. | 2.34% | 2.68% | +0.34% |
| Glenmark Pharmaceuticals Ltd. | 5.63% | 5.39% | -0.24% |
| Ajanta Pharma Ltd. | 2.29% | 2.53% | +0.24% |
| Mankind Pharma Ltd. | 4.11% | 4.35% | +0.24% |
| Sai Life Sciences Ltd. | 3.03% | 3.23% | +0.20% |
| Aster DM Quality Care Ltd. | 3.05% | 2.86% | -0.19% |
| Neuland Laboratories Ltd. | 2.99% | 2.82% | -0.17% |
| Abbott India Ltd. | 2.03% | 2.17% | +0.14% |
| Glaxosmithkline Pharmaceuticals Ltd. | 1.90% | 1.76% | -0.14% |
| Acutaas Chemicals Ltd. | 2.47% | 2.61% | +0.14% |
| Dr. Lal Pathlabs Ltd. | 2.27% | 2.38% | +0.11% |
| Granules India Ltd. | 1.81% | 1.92% | +0.11% |
| Krishna Institute of Medical Sciences Ltd | 2.95% | 3.06% | +0.11% |
| Narayana Hrudayalaya Ltd. | 1.99% | 1.90% | -0.09% |
| Syngene International Ltd. | 1.15% | 1.06% | -0.09% |
| Alkem Laboratories Ltd. | 4.70% | 4.78% | +0.08% |
| Gland Pharma Ltd. | 3.46% | 3.54% | +0.08% |
| Aurobindo Pharma Ltd. | 7.16% | 7.09% | -0.07% |
| Global Health Ltd. | 1.91% | 1.86% | -0.05% |
| Onesource Specialty Pharma Ltd. | 1.80% | 1.84% | +0.04% |
| Piramal Pharma Ltd. | 2.01% | 1.97% | -0.04% |
| Poly Medicure Ltd. | 1.01% | 0.98% | -0.03% |
| Ipca Laboratories Ltd. | 4.13% | 4.11% | -0.02% |
| Cohance Lifesciences Ltd. | 1.12% | 1.11% | -0.01% |
| Natco Pharma Ltd. | 1.14% | 1.14% | 0.00% |
Compare
Similar funds
The rest of the category, so this fund’s numbers have something to sit against.
| Fund | AUM | Expense | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Category average | ₹2,892 Cr | 1.89% | 30.4% | 19.0% | 20.6% |
 SBI Healthcare Opportunities Fund | ₹5,870 Cr | 1.98% | 29.4% | 18.2% | 21.6% |
 HDFC Pharma And Healthcare Fund | ₹3,501 Cr | 2.11% | 33.4% | 23.9% | — |
 Mirae Asset Healthcare Fund | ₹3,494 Cr | 2.01% | 30.8% | 18.3% | 20.0% |
 UTI Healthcare Fund | ₹1,430 Cr | 2.21% | 25.9% | 16.9% | 20.1% |
 ICICI Prudential Nifty Pharma Index Fund | ₹163 Cr | 1.13% | 32.3% | 17.6% | — |
About
About this fund
The scheme’s own words, its benchmark and the people running it.
Investment objective
The scheme seeks to provide returns that, before expenses, correspond to the total returns of the securities as represented by Nifty MidSmall Healthcare Total Return Index, subject to tracking error.
Fund managers
- Dishant MehtaBachelors of Science (B.SC)Mr. Dishant Mehta has more than 11 years of experience and expertise in Financial markets across different segment -Equities, Derivatives, Commodities and Currencies
- Rakesh ShettyMr. Shetty has done B.ComPrior to joining Motilal Oswal Mutual Fund, he has worked with Company engaged in Capital Market Business wherein he was in charge of equity and debt ETFs, customized indices and has also been part of product development.
- Swapnil P MayekarMr. Mayekar is an M.Com from Mumbai University and also holds an Advanced Diploma in Business Administration from Welingkar, Mumbai.Prior to joining Motilal Oswal AMC he worked with Business Standard Limited from Aug 2005 to Feb 2010.
Tools
Return calculator
What ₹10,000 a month in this fund would have grown to over each period, based on its past returns.
| Over the past | Total investment | Would’ve become | Growth | Returns |
|---|---|---|---|---|
| 6 months11.31% absolute | ₹60,000 | ₹66,786 | 11.31% | |
| 1 year19.74% annualised | ₹1,20,000 | ₹1,33,638 | 11.36% |
Returns for 1 year and longer are annualised (CAGR); 6-month figures are absolute. Past returns are not a forecast.
How this is calculated
Each monthly instalment grows at the fund’s annualised return ÷ 12 per month until the end of the period, the same formula as our SIP calculator.
The amount compounds once a year at the fund’s CAGR for that period, the same formula as our lumpsum calculator.
Questions
Frequently asked questions
The things people ask about this scheme.